Dry Eye Target Market $Allergan reported 4Q/08 on Feb 4th, an example of their market for Dry Eye drug Restasis is as follows:
2007 - $344 Million net sales
2008 - $444 Million net sales
2009 - Outlook projected to be between $490 - $510 Million net sales
Obviously a growing market for Restasis(Cyclosporin) and a money maker for Allergan and clearly a target prize market for Lux Bio and the main reason for being founded/capitalized in 2006 to address this lucrative under developed 10 million potential user market (starting with Uveitis and targeting Dry Eye).
https://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=363526
Restasis can take up to 2 weeks of use (1 drop twice daily) for therapuetic benefits with up to 6 months for maximum benefit, so it does not provide immediate relief (Topical Corticosteroids usually prescribed for 2-4 weeks).
https://www.agingeye.net/mainnews/newscan2.php
According to Allergan/Restasis website......dry eye affects an estimated 21 million in the United States.....
RESTASIS® ophthalmic emulsion is the first, and currently the only, prescription eye drop that helps to increase your eyes' natural ability to produce tears which may be suppressed by inflammation due to chronic dry eye. RESTASIS® ophthalmic emulsion did not increase tear production in patients using topical steroid drops or tear duct plugs. Artificial tears provide temporary relief of dry eye symptoms by putting water and lubricants on the surface of the eye. RESTASIS®, approved by the U.S. Food and Drug Administration in 2002, is currently the only prescription eye drop believed to address an underlying cause of chronic dry eye.
https://www.allergan.com/products/eye_care/restasis.htm
IMO this could potentially be a big indication for both ISA / Lux Bio with many marketable advantages in a market with over the counter treatments but currently only one prescription (Restasis). If the trial results are good with Uveitis (Luveniq) and Dry Eye (LX214), I certainly would see Lux trying to capitalize on its investment pipeline as soon as it can for market share and returns.